Detalles de la búsqueda
1.
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
Invest New Drugs
; 36(4): 536-544, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29188469
2.
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Oncotarget
; 11(17): 1478-1492, 2020 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32391118
3.
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Clin Cancer Res
; 25(7): 2278-2289, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30563935
4.
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Oncotarget
; 9(17): 13796-13806, 2018 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29568395
5.
LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Clin Cancer Res
; 20(23): 6059-70, 2014 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25231402
6.
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Cancer Res
; 71(5): 1849-57, 2011 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21233335
Resultados
1 -
6
de 6
1
Próxima >
>>